NasdaqGS - Nasdaq Real Time Price USD

Erasca, Inc. (ERAS)

1.2300
-0.0550
(-4.28%)
At close: May 19 at 4:00:01 PM EDT
1.2600
+0.03
+(2.44%)
After hours: May 19 at 6:53:32 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
153,866
157,087
141,525
145,450
96,538
Operating Income
-153,866
-157,087
-141,525
-145,450
-96,538
Net Non Operating Interest Income Expense
20,933
20,093
16,712
4,902
190
Other Income Expense
-24,666
-24,656
-229
-102,257
-26,416
Pretax Income
-157,599
-161,650
-125,042
-242,805
-122,764
Net Income Common Stockholders
-157,599
-161,650
-125,042
-242,805
-122,764
Diluted NI Available to Com Stockholders
-157,599
-161,650
-125,042
-242,805
-122,764
Basic EPS
-0.57
-0.69
-0.83
-1.99
-1.85
Diluted EPS
-0.57
-0.69
-0.83
-1.99
-1.85
Basic Average Shares
266,842.5530
233,817.9160
150,184.9940
122,024.8480
66,290.5920
Diluted Average Shares
266,842.5530
233,817.9160
150,184.9940
122,024.8480
66,290.5920
Total Operating Income as Reported
-176,366
-179,587
-141,525
-247,450
-124,883
Total Expenses
153,866
157,087
141,525
145,450
96,538
Net Income from Continuing & Discontinued Operation
-157,599
-161,650
-125,042
-242,805
-122,764
Normalized Income
-135,099
-139,150
-125,042
-140,805
-94,419
Interest Income
20,933
20,093
16,712
4,902
190
Net Interest Income
20,933
20,093
16,712
4,902
190
EBIT
-153,866
-157,087
-141,525
-145,450
-96,538
EBITDA
-150,237
-153,282
-137,793
-142,809
-95,709
Reconciled Depreciation
3,629
3,805
3,732
2,641
829
Net Income from Continuing Operation Net Minority Interest
-157,599
-161,650
-125,042
-242,805
-122,764
Total Unusual Items Excluding Goodwill
-22,500
-22,500
0
-102,000
-28,345
Total Unusual Items
-22,500
-22,500
0
-102,000
-28,345
Normalized EBITDA
-127,737
-130,782
-137,793
-40,809
-67,364
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DSGN Design Therapeutics, Inc.
3.5300
+0.57%
 
CGEM Cullinan Therapeutics, Inc.
7.71
+2.80%
 
ORIC ORIC Pharmaceuticals, Inc.
5.14
+8.67%
 
LYEL Lyell Immunopharma, Inc.
0.4131
-0.46%
 
GLUE Monte Rosa Therapeutics, Inc.
4.1100
+3.27%
 
OLMA Olema Pharmaceuticals, Inc.
4.8000
+1.91%
 
EWTX Edgewise Therapeutics, Inc.
14.79
+0.07%
 
IPSC Century Therapeutics, Inc.
0.5543
-1.02%
 
APGE Apogee Therapeutics, Inc.
39.91
-1.75%
 
RVMD Revolution Medicines, Inc.
39.93
+0.99%